The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).
 
Ravindra Uppaluri
Consulting or Advisory Role - Merck
Research Funding - Merck
 
Rebecca Chernock
Consulting or Advisory Role - Merck; Roche
Travel, Accommodations, Expenses - Roche
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Caris Life Sciences
 
Mena Mansour
No Relationships to Disclose
 
Ryan Jackson
No Relationships to Disclose
 
Jason Rich
No Relationships to Disclose
 
Patrik Pipkorn
No Relationships to Disclose
 
Randal C Paniello
No Relationships to Disclose
 
Sidharth Puram
No Relationships to Disclose
 
Jose P. Zevallos
Stock and Other Ownership Interests - Droplet Biosciences; Summit Biolabs
 
Donald J. Annino
No Relationships to Disclose
 
Laura A. Goguen
No Relationships to Disclose
 
Luc Morris
Consulting or Advisory Role - Rakuten Aspyrian
Research Funding - AstraZeneca; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - employer pending patent application, listed as inventor (Inst)
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; BioNTech; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Pfizer; Vaccinex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst); VentiRx (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - ISA Pharmaceuticals; Nanobiotix
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Bicara Therapeutics; Bio-Rad; Bristol-Myers Squibb; Exicure; Kura Oncology; Maverick Therapeutics; Merck; Naveris; Prelude Therapeutics; Regeneron; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); EMD Serono (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Maverick Therapeutics; Regeneron
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
 
Lara Dunn
Consulting or Advisory Role - CUE Biopharma; CUE Biopharma; Regeneron
Research Funding - Eisai; Pfizer; Regeneron
 
Jessica C. Ley
No Relationships to Disclose
 
Dorina Kallogjeri
No Relationships to Disclose
 
Ann Marie Egloff
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; CUE Biopharma; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Exelixis (Inst); Innate Pharma (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst)